

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kaylor, et al.

Docket No: KCX-930 (16926)

Serial No: 10/026,415

Group No: 1743

Confirmation No: 2521

Examiner: Lyle Alexander

Customer No: 22827

Filed: December 21, 2001

Date: January 27, 2005

For: Diagnostic Device, System And Method

**RELATED U.S. PATENT APPLICATION**

ASSISTANT COMMISSIONER FOR PATENTS


P.O. Box 1450

Alexandria, VA 22313-1450

The following commonly assigned U.S. Patent Application is being cited to the Examiner for review and consideration. Once the application has been reviewed, it is requested that the Examiner place his or her initial to the left of the identified patent on the list document to indicate that the specific patent application has been considered.

**RELATED U.S. APPLICATIONS**

<u>Examiner's Initial</u>	<u>Inventor</u>	<u>Serial Number</u>	<u>Filing Date</u>	<u>Title of Application</u>
_____	Cohen, et al.	11/021,545	12/23/2004	Microfluidic Assay Devices



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Kaylor, et al. )  
Serial No: 10/026,415 )  
Filed: December 21, 2001 )  
Confirmation No: 2521 )  
Title: Diagnostic Device, System And Method )  
Group Art Unit: 1743  
Examiner: Lyle Alexander  
Our Account No: 04-1403  
Customer No: 22827

Commissioner for Patents  
U.S. Patent and Trademark Office  
Post Office Box 1450  
Alexandria, VA 22313-1450

Sir:

The following is an Information Disclosure Statement for the captioned patent application, pursuant to 37 CFR Sections 1.56, 1.97, and 1.98.

1.[x] Attached hereto is:

- a.[x] A list of materials for consideration per Rule 98(a)(1): 2 page(s)
- b.[x] A legible copy of each patent, publication, or other item listed per Rule 98(1)(2), unless not required per Rule 98 and/or as indicated on the attached list(s):  
46 item(s)
- c.[ ] For each non-English language item listed, pursuant to Rule 98(a)(3), a concise explanation of the relevance thereof as it is presently understood by the individual designated in Rule 56(c) most knowledgeable about the content of such items: \_\_\_\_\_  
[ ] Such explanation is provided in the Search Report from a corresponding application enclosed herewith along with any enclosed translation into English.

2.[x] This Information Disclosure Statement is being filed [CHECK ONE]:

- a.[x] WITHIN THREE MONTHS of the application filing date, national stage date of entry, or along with or after a request for continued examination, OR BEFORE the mailing date of a first Office Action on the merits, which ever event occurs last, WHEREFORE per Rule 97(b) NO filing fee or Rule 97(e) certificate is required.
- b.[ ] AFTER the time periods of section 2.a above, but BEFORE a Final Action, Notice of Allowance OR an action that otherwise closes prosecution, WHEREFORE PER Rule 97(c) submitted herewith is [CHECK ONE]:
  - i.[ ] Certification per Rule 97(e); OR
  - ii.[ ] Filing Fee per Rule 17(p) .....\$180.00
- c.[ ] AFTER a Final Action OR Notice of Allowance, but BEFORE payment of the issue fee, WHEREFORE per Rule 97(d) submitted herewith is:
  - i. Certification per Rule 97(e); AND
  - ii. Filing fee per Rule 17(p) .....\$180.00

3.[ ] Rule 97(e) Certification; per Rule 97(e), the undersigned certifying party make the following certification statement [CHECK ONE]:

- a.[ ] That each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; OR
- b.[ ] That no item of information contained in this Information Disclosure Statement was cited in a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making a reasonable inquiry, was known to any individual designated in Rule 56(c) more than three months prior to the filing of this statement.

CERTIFYING PARTY (if different from bottom signature; omission here indicates that certification is being made by signer per signature below).

Name: \_\_\_\_\_  
Address: \_\_\_\_\_

Signature: \_\_\_\_\_  
Date: \_\_\_\_\_

4.[x] DEPOSIT ACCOUNT AUTHORIZATION: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. This statement does not authorize charge of the issue fee in this case.

5.[x] CERTIFICATE OF MAILING: This Information Disclosure Statement is being filed pursuant to [CHECK AND COMPLETE ONE]:

a.[x] First Class Mail Certificate of Mailing under Rule 8:

I hereby certify that this correspondence and any referenced attachment and/or fee are being deposited with the United States Postal Service as first class mail in an envelope addressed to the:

Commissioner for Patents  
U.S. Patent and Trademark Office  
Post Office Box 1450  
Alexandria, VA 22313-1450

on January 27, 2005.

Lynn Watkins  
(Typed/printed name of person mailing paper or fee)

[Signature]  
(Signature of person mailing paper or fee)

b.[ ] "Express Mail" Certificate under Rule 10:

"Express Mail" - Label No. \_\_\_\_\_  
Date of Deposit \_\_\_\_\_

I hereby certify that this paper and all attachments and any fee are being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the:

Commissioner for Patents  
U.S. Patent and Trademark Office  
Post Office Box 1450  
Alexandria, VA 22313-1450.

\_\_\_\_\_  
(Typed/printed name of person mailing paper or fee)

\_\_\_\_\_  
(Signature of person mailing paper or fee)

ADDRESS:  
Post Office Box 1449  
Greenville, SC 29602 USA  
Customer ID No.: 22827  
Telephone: 864-271-1592  
Facsimile: 864-233-7342


DORITY & MANNING, ATTORNEYS AT LAW, P.A.

By: Jason W. Johnston

Reg. No: 45,675

Signature: [Signature]

Date: January 27, 2005



(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: KCX-930 (16926)	Serial Number: 10/026,415
	Applicant: Kaylor, et al.	
	Filing Date: December 21, 2001 Confirmation No: 2521	Group Art Unit: 1743

U.S. PATENT DOCUMENTS										
EXAMINER INITIALS	PATENTEE NAME	PATENT NUMBER							ISSUE DATE	COPY NOTE
	Stave, et al.	6	6	6	3	8	3	3	12/16/2003	
	Anderson, et al.	6	6	8	6	1	8	4	02/03/2004	
	Schulte, et al.	6	7	4	2	6	6	1	06/01/2004	
	Weigle, et al.	6	7	4	2	3	9	9	06/01/2004	
	Widrig Opalsky, et al.	6	7	5	0	0	5	3	06/15/2004	

U.S. PATENT APPLICATION PUBLICATIONS										
EXAMINER INITIALS	APPLICANT'S NAME	PUBLICATION NUMBER							PUBLICATION DATE	COPY NOTE
	Kaylor, et al. 2003	0	1	0	7	7	4	0	06/12/2003	
	Quirk, et al. 2003	0	1	1	8	4	7	9	06/26/2003	
	Kaylor, et al. 2003	0	1	1	9	2	0	9	06/26/2003	
	Kaylor, et al. 2003	0	2	0	7	2	5	3	11/06/2003	

FOREIGN PATENT DOCUMENTS										
EXAMINER INITIALS	COUNTRY	DOCUMENT NUMBER							PUBLICATION DATE	TRANSLATION
										YES NO N/A
	WO	0	1	8	1	9	2	1	11/01/2001	X

\*\*"NO" means that no copy of an English language translation is within the possession, custody, or control of, or is readily available to any individual designated in Rule 56(c).

EXAMINER INITIALS	OTHER DOCUMENTS	COPY NOTE
	Specify author (if any), Title, Pertinent Pages, Date & Place of Publication	
	Article - <i>Formation of Droplets and Mixing in Multiphase Microfluidics at Low Values of the Reynolds and the Capillary Numbers</i> , Joshua D. Tice, Helen Song, Adam D. Lyon, and Rustem F. Ismagilov, Langmuir, Vol. 19, No. 22, 2003, pp. 9127-9133	
EXAMINER	DATE CONSIDERED	
Examiner: initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.		

BEST AVAILABLE COPY

(Rev. 5/92)

## Information Disclosure Statement List

By Applicant(s)

Under 37 CFR Section 1.98(a) (1)

(Use several sheets if necessary)

Attorney Docket Number:

KCX-930 (16926)

Serial Number:

10/026,415

Applicant:

Kaylor, et al.

Filing Date:

December 21, 2001

Confirmation No:

2521

Group Art Unit:

1743

## NOTE:

If no indication is made in the column marked "COPY NOTE," the required legible copy of the corresponding item is submitted herewith; otherwise, a copy is not required and/or not submitted, for the following reason(s) [corresponding reason number is listed in "COPY NOTE" column]"

- (1) This item is cumulative, per Rule 98(c)
- (2) A copy of this item was previously cited by or submitted to the U.S. Patent and Trademark Office in:  
     USSN \_\_\_\_\_, filed \_\_\_\_\_, or  
     USSN \_\_\_\_\_, filed \_\_\_\_\_;  
     Relied on under 35 U.S.C. Section 120, per Rule 98(d)
- (3) Both reasons (1) and (2) apply
- (4) No legible complete copy is possessed, in custody of controlled, or readily available
- (5) Per the U.S. Patent and Trademark Office's waiver of Rule 98(a)(2)(i), the item is a U.S. patent or patent application publication, and the present application was filed after June 30, 2003.

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	PATENTEE NAME	PATENT NUMBER								ISSUE DATE	COPY NOTE
	Tom, et al. (RE)	4	3	6	6	2	4	1		10/18/1988	
	Nicoli, et al.	4	6	4	7	5	4	4		03/03/1987	
	Tarcha, et al.	5	2	5	2	4	5	9		10/12/1993	
	Walling, et al.	5	5	0	8	1	7	1		04/16/1996	
	Kumar, et al.	5	5	1	2	1	3	1		04/30/1996	
	Vreeke, et al.	5	5	3	4	1	3	2		07/09/1996	
	Lauks, et al.	5	6	3	8	8	2	8		06/17/1997	
	Lauks, et al.	5	6	5	3	2	4	3		08/05/1997	
	Lauks, et al.	5	6	6	6	9	6	7		09/16/1997	
	Jou, et al.	5	6	7	0	3	8	1		09/23/1997	
	Lauks, et al.	5	7	7	9	6	5	0		07/14/1998	
	Cozzette, et al.	5	8	3	7	4	5	4		11/17/1998	
	Kopf-Sill, et al.	5	8	4	2	7	8	7		12/01/1998	
	Lauks, et al.	6	0	1	0	4	6	3		01/04/2000	
	Davis, et al.	6	0	3	0	8	2	7		02/29/2000	
	Kellogg, et al.	6	0	6	3	5	8	9		05/16/2000	
	Sheppard, Jr., et al.	6	1	4	3	2	4	7		11/07/2000	
	Kellogg, et al.	6	1	4	3	2	4	8		11/07/2000	
	Monbouquette	6	2	4	1	8	6	3		06/05/2001	
	Crismore, et al.	6	2	7	0	6	3	7		08/07/2001	
	Heller, et al.	6	2	8	1	0	0	6		08/28/2001	
	Kuhr, et al.	6	2	9	4	3	9	2		09/25/2001	
	Wainright, et al.	6	3	0	6	2	7	3		10/23/2001	
	Davis, et al.	6	3	7	9	8	8	3		04/30/2002	
	Kaylor, et al.	6	3	9	9	2	9	5		06/04/2002	
	Alajoki, et al.	6	4	1	6	6	4	2		07/09/2002	
	Everhart, et al.	6	4	3	6	6	5	1		08/20/2002	
	Feldman, et al.	6	4	6	1	4	9	6		10/08/2002	
	O'Connor, et al.	6	4	8	1	4	5	3		11/19/2002	
	Kennedy	6	5	0	9	0	8	5		01/21/2003	
	Parce, et al.	6	5	1	4	3	9	9		02/04/2003	
	Everhart, et al.	6	5	7	3	0	4	0		06/03/2003	
	McGrath, et al.	6	5	7	9	6	7	3		06/17/2003	
	Kellogg, et al.	6	5	8	2	6	6	2		06/24/2003	
	Yang, et al.	6	6	3	2	6	2	9		10/14/2003	

BEST AVAILABLE COPY